60 DEGREES PHARMACEUTICALS, INC. (SXTP)
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
60 Degrees Pharmaceuticals, Inc.
NASDAQ:SXTPHealthcare · Biotechnology
-0.79%$0.9400
AH$0.9400+0.00%vs close
Mkt Cap$3.31M
Float3.48M
O/S3.52M
Vol
$ Vol
RVOL
Inst Own13.5%
SI3.9%
Earnings
Dilution
Financials Summary
Revenue$1.01M
Net Income-$7.37M
Total Assets$5.37M
Free Cash Flow-$7.07M
Debt & Equity
Debt 1%
Equity 26%
Preferred 73%
Total Debt$153K
Total Equity$3.46M
Preferred Stock$9.57M
Shares Outstanding
Short Interest
Split History3 splits · 3 reverse
2-year cumulative
1:20
Nasdaq bars a compliance period at 1:250
- 1:4Reverse splitJan 20, 20264 shares → 1
- 1:5Reverse splitFeb 24, 20255 shares → 1
- 1:12Reverse splitAug 12, 202412 shares → 1
Balance Sheet Details
Assets$5.37M
Liabilities$1.99M
Accounts Receivable$510K
Accounts Payable$1.46M
Inventory$657K
PP&E (Net)$246K
Goodwill$0
Intangible Assets$224K
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $1.01M | $608K | $254K | $223K | $1.16M | $2.18M |
| YoY Growth | 65.5% | 139.6% | 13.6% | -80.8% | -46.8% | - |
| Cost of Revenue | $782K | $385K | $475K | $432K | $851K | $703K |
| Gross Profit | $224K | $223K | -$221K | -$209K | $310K | $1.48M |
| Gross Margin | 22.3% | 36.7% | -87.1% | -93.7% | 26.7% | 67.8% |
| Research and Development | $2.11M | $4.99M | $692K | $526K | $5.51M | $807K |
| Selling, General, and Administrative | $6.28M | $5.02M | $4.24M | $1.3M | $1.12M | $1.46M |
| Other | -$404K | -$74K | $0 | -$288K | -$5.19M | -$368K |
| Total Operating Expenses | $7.98M | $9.94M | $4.93M | $1.54M | $1.43M | $1.9M |
| Operating Income (EBIT) | -$7.76M | -$9.71M | -$5.15M | -$1.75M | -$1.12M | -$418K |
| Operating Margin | -771.6% | -1599.0% | -2032.8% | -784.2% | -96.9% | -19.2% |
| Interest Expense | $8K | $8K | $2.29M | $3.99M | $3.17M | $2.68M |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | $390K | $1.76M | $1.34M | -$4.43M | -$3.14M | -$2.63M |
| Income Before Tax (EBT) | -$7.37M | -$7.96M | -$3.81M | -$6.18M | -$4.26M | -$3.05M |
| Income Tax Expense | $0 | $250 | $250 | $500 | $1K | $1K |
| Net Income | -$7.37M | -$7.95M | -$3.77M | -$6.18M | -$4.25M | -$3.03M |
| Net Income Margin | -732.8% | -1308.0% | -1485.1% | -2769.5% | -366.4% | -139.1% |
| Supplementary Data | ||||||
| EPS | -11.73 | -74.20 | -3.80 | -4.28 | -2.96 | -2.08 |
| Diluted EPS | -11.73 | -74.20 | -3.80 | -4.28 | -2.96 | -2.08 |
| Weighted Average OS | 670,211 | 113,665 | 24,208 | 24,208 | 24,208 | 24,208 |
| EBITDA | -$7.28M | -$7.88M | -$1.43M | -$2.11M | -$1.01M | -$341K |
| EBITDA Margin | -723.8% | -1297.6% | -562.6% | -944.9% | -87.5% | -15.6% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $1.51M | $1.66M | $2.14M | $265K | $115K | $192K |
| Short-Term Investments | $1.24M | $1.73M | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $2.75M | $3.39M | $2.14M | $265K | $115K | $192K |
| Accounts Receivable | $510K | $487K | $231K | $46K | $146K | $859K |
| Inventory | $657K | $443K | $466K | $519K | $689K | $1.04M |
| Other Current Assets | $978K | $1.07M | $2.73M | $69K | $0 | $352K |
| Total Current Assets | $4.9M | $5.39M | $7.24M | $1.1M | $1.18M | $2.44M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $246K | $150K | $71K | $34K | $108K | $73K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $224K | $157K | $227K | $164K | $109K | $80K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $66K | $243K | $0 | $0 | $10K |
| Total Long-Term Assets | $471K | $373K | $541K | $198K | $217K | $163K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $5.37M | $5.76M | $7.78M | $1.3M | $1.39M | $2.61M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $1.46M | $1.01M | $506K | $759K | $589K | $1.38M |
| Short-Term Debt | $9K | $9K | $9K | $21.14M | $94K | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $1K | $1K |
| Current Unearned Revenue | $0 | $0 | $0 | $325K | $0 | $0 |
| Other Current Liabilities | $375K | $641K | $2.31M | $1.49M | -$94K | $2K |
| Total Current Liabilities | $1.84M | $1.66M | $2.84M | $23.92M | $635K | $1.43M |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $144K | $147K | $150K | $1.27M | $18.74M | $15.92M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $103K |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $255K | $155K | $3.22M |
| Total Long-Term Liabilities | $144K | $147K | $150K | $1.53M | $18.91M | $19.24M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.99M | $1.8M | $2.99M | $25.45M | $19.55M | $20.68M |
| Stockholders' Equity | ||||||
| Preferred Stock | $9.57M | $9.57M | $9.86M | $0 | $0 | $0 |
| Common Stock | $116 | $57 | $10 | $239 | $4.98M | $800K |
| Retained Earnings | -$47.89M | -$40.53M | -$32.58M | -$28.82M | -$22.63M | -$18.38M |
| Comprehensive Income & Other | $143K | $135K | $136K | $74K | $76K | $80K |
| Other Stockholders' Equity | $51.36M | $44.56M | $37.45M | $5.24M | $76K | $80K |
| Total Equity | $3.46M | $4.04M | $4.87M | -$23.58M | -$17.58M | -$17.5M |
| Minority Interest | -$84K | -$81K | -$72K | -$572K | -$576K | -$569K |
| Total Liabilities and Equity | $5.45M | $5.84M | $7.86M | $1.87M | $1.97M | $3.18M |
| Supplementary Data | ||||||
| Total Debt | $153K | $156K | $173K | $22.42M | $18.8M | $15.92M |
| Net Debt | -$1.36M | -$1.5M | -$1.97M | $22.15M | $18.69M | $15.73M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$7.37M | -$7.96M | -$3.77M | -$6.18M | -$4.26M | -$3.05M |
| Depreciation & Amortization | $83K | $64K | $100K | $79K | $72K | $28K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $456K | $3.61M | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | ||||||
| Accounts Receivable | -$23K | -$255K | -$185K | $100K | $713K | -$660K |
| Inventory | -$466K | $23K | $213K | -$53K | $312K | $191K |
| Accounts Payable | $491K | $501K | -$215K | $170K | -$845K | $796K |
| Other Working Capital | -$8K | -$77K | $593K | $3.09M | $2.72M | $2.1M |
| Total Working Capital Change | -$6K | $193K | $405K | $3.31M | $2.9M | $2.43M |
| Other Non-Cash Items | -$14K | -$1.56M | -$1.28M | $1.78M | $643K | $426K |
| Net Cash from Operating | -$6.85M | -$5.65M | -$4.54M | -$1.01M | -$649K | -$167K |
| Investing Activities | ||||||
| Capital Expenditures | -$218K | -$104K | -$58K | -$60K | -$3K | -$71K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$1.24M | -$1.71M | $0 | $0 | $0 | $0 |
| Sales of Investments | $1.71M | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$77K | -$58K | $0 | -$32K | $0 |
| Net Cash from Investing | $255K | -$1.89M | -$116K | -$60K | -$35K | -$71K |
| Financing Activities | ||||||
| Debt Repaid | - | - | $961K | -$1.1M | -$611K | -$277K |
| Common Stock Issuance | $6.46M | $7.04M | $6.45M | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$18K | $11K | $981K | $117K | $0 | $0 |
| Net Cash from Financing | $6.44M | $7.05M | $6.47M | $1.22M | $611K | $277K |
| Forex Effect | $7K | $499 | $62K | -$2K | -$3K | -$134K |
| Net Change in Cash | -$149K | -$483K | $1.88M | $149K | -$76K | -$95K |
| Supplementary Data | ||||||
| Operating Cash Flow | -$6.85M | -$5.65M | -$4.54M | -$1.01M | -$649K | -$167K |
| Capital Expenditure | -$218K | -$181K | -$116K | -$60K | -$35K | -$71K |
| Free Cash Flow | -$7.07M | -$5.83M | -$4.66M | -$1.07M | -$684K | -$238K |
| Cash at Beginning | $1.66M | $2.14M | $265K | $115K | $192K | $287K |
| Cash at End | $1.51M | $1.66M | $2.14M | $265K | $115K | $192K |